+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biodefense Market by Product Type, Application, End User, Distribution Channel, Pathogen Type - Global Forecast to 2030- Product Image
Biodefense Market by Product Type, Application, End User, Distribution Channel, Pathogen Type - Global Forecast to 2030- Product Image
Sale

Biodefense Market by Product Type, Application, End User, Distribution Channel, Pathogen Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 186 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6082678
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biodefense Market grew from USD 20.33 billion in 2024 to USD 22.71 billion in 2025. It is expected to continue growing at a CAGR of 11.35%, reaching USD 38.77 billion by 2030.

Framing the New Imperatives in Biodefense Strategy

In an era defined by heightened global health threats and rapid technological progress, the role of biodefense has taken on unprecedented significance. Nations and organizations are grappling with the dual challenge of preparing for naturally occurring pandemics and countering potential bioterrorism. The intersection of advanced diagnostics, novel therapeutics, and next-generation vaccines underscores a paradigm shift in how we approach biological threats. Robust surveillance networks, innovative laboratory techniques, and integrated data systems are now pillars of national security.

Amid escalating concerns over pathogen emergence and geopolitical tensions, stakeholders across government, industry, and academia are forging new alliances. Collaborative initiatives are driving accelerated timelines for product development and regulatory approvals. Simultaneously, investment landscapes are evolving as venture capital and public funding converge to support disruptive platforms in immunoassays, molecular diagnostics, and mRNA vaccines. This introduction sets the stage for a deep dive into the catalysts reshaping the biodefense market and the strategic imperatives that will define tomorrow’s resilience.

How Technological and Geopolitical Forces Are Redefining Biodefense

Over the past five years, the biodefense landscape has undergone transformative shifts driven by technological breakthroughs, shifting geopolitical dynamics, and intensified public health priorities. Artificial intelligence and machine learning are uncovering patterns in pathogen behavior that were previously undetectable, reshaping early-warning systems and streamlining drug discovery pipelines. Simultaneously, the decentralization of manufacturing through modular and distributed facilities is mitigating supply chain vulnerabilities and enabling rapid scale-up in response to outbreaks.

Geopolitical flux has prompted governments to reassess national stockpiles and fortify domestic capabilities, fostering growth in homegrown diagnostics and vaccine production. Public-private partnerships have become the backbone of innovation ecosystems, bridging resource gaps and accelerating translational research. These combined forces are redefining the competitive landscape, elevating agility and cross-sector collaboration as prerequisites for success in an increasingly complex threat environment.

Assessing the 2025 Tariff Impact on Biodefense Supply Chains

The introduction of United States tariffs on critical inputs and finished goods in 2025 has generated ripple effects throughout the biodefense supply chain. Increased duties on raw materials for lipid nanoparticles and specialized reagents have led manufacturers to reevaluate sourcing strategies, prompting a shift toward domestically produced alternatives. This realignment has sparked fresh investments in local production capacities, albeit with initial cost escalations.

For global players, the cumulative tariff burden has necessitated pricing adjustments and supply chain redundancies to ensure consistent delivery of diagnostics and therapeutics. Some companies have diversified their supplier base across multiple regions to circumvent tariff exposure, while others have pursued vertical integration to consolidate operations. Regulatory agencies have responded by streamlining approval pathways for domestically manufactured components, seeking to counterbalance cost pressures and reinforce national preparedness.

Deep Dive into Market Segmentation Dynamics

Segmentation insights reveal that the biodefense market’s complexity is best understood through its diverse product offerings. Diagnostics encompasses immunoassays and molecular diagnostics as well as point of care testing; immunoassays extend into Elisa and lateral flow formats; molecular approaches range from isothermal amplification to next generation sequencing and polymerase chain reaction. Therapeutics spans antibacterials, antitoxins, and antivirals, while vaccines cover mRNA platforms built on lipid nanoparticles and self-amplifying constructs alongside protein subunit innovations and viral vectors including adenovirus and poxvirus systems. Applications are equally broad, addressing detection and diagnostics as well as prevention and treatment pathways. End users vary from government agencies to hospitals and clinics to pharmaceutical and biotech companies and research laboratories. Distribution channels blend direct sales engagements with traditional distributors and emerging online platforms. Pathogen type segmentation brings into focus bacterial agents, toxins, and viral threats. Recognizing these interconnected segments allows stakeholders to tailor strategies, optimize portfolio allocations, and align investments with emerging demand pockets.

Uncovering the Regional Drivers Shaping Biodefense Growth

Regional nuances demonstrate that the Americas continue to lead in research intensity and infrastructure investments, driven by strong federal funding and a mature private sector ecosystem. North American capabilities in molecular diagnostics and mRNA vaccine platforms remain world-class, and robust procurement mechanisms ensure rapid deployment during health emergencies. Over in Europe, Middle East & Africa, collaborative frameworks between the European Union and regional health authorities are strengthening surveillance networks and harmonizing regulatory standards. Local manufacturing hubs in Western Europe are complemented by capacity expansion initiatives across the Middle East and North Africa to counter supply chain disruptions.

In the Asia-Pacific, a surge in public funding has spurred domestic players to innovate in low-cost point of care testing and antiviral therapeutics. Partnerships between governments and private firms are accelerating the scale-up of vaccine production, particularly in Southeast Asia. Cross-border alliances with established biotech clusters have enhanced technology transfer and capacity building, positioning the region as both a manufacturing powerhouse and an emerging hub for research and development.

Strategic Moves from Top Biodefense Market Players

Leading organizations are deploying differentiated strategies to capture value in the evolving biodefense arena. Major pharmaceutical firms are integrating next generation sequencing capabilities to bolster pathogen surveillance while expanding their antiviral pipelines through strategic acquisitions. Specialty biotech companies are focusing on modular manufacturing technologies and advanced delivery systems for mRNA and protein subunit vaccines. Partnerships between diagnostics innovators and laboratory service providers are accelerating rollout of point of care platforms suitable for decentralized deployments.

Meanwhile, contract research and manufacturing organizations are scaling up to offer end-to-end support across development, clinical trials, and regulatory submissions. Collaborative alliances between academic institutions and industry players are becoming more prevalent, catalyzing translational breakthroughs in immunoassays and novel therapeutic modalities. These diverse approaches reflect a competitive landscape in which agility, technological prowess, and ecosystem integration determine market leadership.

Proven Strategies to Enhance Biodefense Preparedness

Industry leaders should prioritize building resilient supply chains that incorporate multiple sourcing options and localized production capabilities to withstand tariff disruptions and logistical uncertainties. Investing in digital platforms for real-time data sharing across stakeholders will enhance situational awareness and expedite decision-making. Accelerating cross-sector collaborations between government agencies, academic centers, and private enterprises can drive faster innovation cycles and reduce development timelines.

Embracing scalable manufacturing technologies such as modular facilities and continuous flow processes will enable rapid surge capacity during crises. Leaders must also cultivate talent pipelines with interdisciplinary expertise in bioinformatics, regulatory science, and advanced manufacturing. Finally, adopting a portfolio-based investment approach across diagnostics, therapeutics, and vaccines will distribute risk and maximize the potential for high-impact breakthroughs in biodefense.

Robust Methodology Underpinning Our Insights

This analysis synthesizes insights from a rigorous multi-stage research framework combining both primary and secondary sources. The secondary research phase encompassed a thorough review of peer-reviewed journals, industry whitepapers, and regulatory filings to map historical trends and identify emerging technologies. In parallel, primary research involved in-depth interviews with over thirty subject matter experts spanning government biodefense agencies, leading biotechnology firms, and academic research centers.

Data validation protocols ensured consistency by triangulating findings across multiple data points and cross-referencing proprietary databases. Market segmentation was refined through iterative feedback loops with industry stakeholders to guarantee alignment with real-world applications. The final synthesis underwent peer review by an external panel of regulatory and technical advisors to affirm accuracy and relevance.

Synthesizing Insights for Future Biodefense Success

Biodefense stands at a pivotal juncture, shaped by technological innovations, geopolitical imperatives, and evolving threat landscapes. The insights presented here underscore the necessity of integrated strategies spanning diagnostics, therapeutics, and vaccine development, tailored by nuanced segmentation and regional dynamics. By understanding the cumulative effects of policy actions such as tariffs, companies can optimize their operations and forge sustainable competitive advantages.

The collaborative spirit between public and private sectors, coupled with investments in advanced manufacturing and data-driven tools, will define the next wave of biodefense resilience. As the global community braces for future biological challenges, informed decision-making and strategic agility will be the keystones of effective preparedness and response.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Diagnostics
      • Immunoassays
        • Elisa
        • Lateral Flow Assays
      • Molecular Diagnostics
        • Isothermal Amplification
        • Next Generation Sequencing
        • Polymerase Chain Reaction
      • Point Of Care Testing
    • Therapeutics
      • Antibacterials
      • Antitoxins
      • Antivirals
    • Vaccines
      • MRNA Vaccines
        • Lipid Nanoparticles
        • Self Amplifying MRNA
      • Protein Subunit Vaccines
      • Viral Vector Vaccines
        • Adenovirus Based
        • Poxvirus Based
  • Application
    • Detection & Diagnostics
    • Prevention
    • Treatment
  • End User
    • Government Agencies
    • Hospitals & Clinics
    • Pharma & Biotech Companies
    • Research Laboratories
  • Distribution Channel
    • Direct Sales
    • Distributors
    • Online Channels
  • Pathogen Type
    • Bacterial Agents
    • Toxins
    • Viral Agents
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Merck KGaA
  • Bio-Rad Laboratories, Inc.
  • PerkinElmer, Inc.
  • QIAGEN N.V.
  • bioMérieux SA
  • Agilent Technologies, Inc.
  • Bruker Corporation
  • Luminex Corporation

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biodefense Market, by Product Type
8.1. Introduction
8.2. Diagnostics
8.2.1. Immunoassays
8.2.1.1. Elisa
8.2.1.2. Lateral Flow Assays
8.2.2. Molecular Diagnostics
8.2.2.1. Isothermal Amplification
8.2.2.2. Next Generation Sequencing
8.2.2.3. Polymerase Chain Reaction
8.2.3. Point Of Care Testing
8.3. Therapeutics
8.3.1. Antibacterials
8.3.2. Antitoxins
8.3.3. Antivirals
8.4. Vaccines
8.4.1. MRNA Vaccines
8.4.1.1. Lipid Nanoparticles
8.4.1.2. Self Amplifying MRNA
8.4.2. Protein Subunit Vaccines
8.4.3. Viral Vector Vaccines
8.4.3.1. Adenovirus Based
8.4.3.2. Poxvirus Based
9. Biodefense Market, by Application
9.1. Introduction
9.2. Detection & Diagnostics
9.3. Prevention
9.4. Treatment
10. Biodefense Market, by End User
10.1. Introduction
10.2. Government Agencies
10.3. Hospitals & Clinics
10.4. Pharma & Biotech Companies
10.5. Research Laboratories
11. Biodefense Market, by Distribution Channel
11.1. Introduction
11.2. Direct Sales
11.3. Distributors
11.4. Online Channels
12. Biodefense Market, by Pathogen Type
12.1. Introduction
12.2. Bacterial Agents
12.3. Toxins
12.4. Viral Agents
13. Americas Biodefense Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Biodefense Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Biodefense Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Thermo Fisher Scientific Inc.
16.3.2. Danaher Corporation
16.3.3. Merck KGaA
16.3.4. Bio-Rad Laboratories, Inc.
16.3.5. PerkinElmer, Inc.
16.3.6. QIAGEN N.V.
16.3.7. bioMérieux SA
16.3.8. Agilent Technologies, Inc.
16.3.9. Bruker Corporation
16.3.10. Luminex Corporation
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. BIODEFENSE MARKET MULTI-CURRENCY
FIGURE 2. BIODEFENSE MARKET MULTI-LANGUAGE
FIGURE 3. BIODEFENSE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIODEFENSE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIODEFENSE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIODEFENSE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIODEFENSE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIODEFENSE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIODEFENSE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BIODEFENSE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES BIODEFENSE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. BIODEFENSE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. BIODEFENSE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIODEFENSE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIODEFENSE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIODEFENSE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIODEFENSE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIODEFENSE MARKET SIZE, BY ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIODEFENSE MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIODEFENSE MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIODEFENSE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIODEFENSE MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIODEFENSE MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIODEFENSE MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIODEFENSE MARKET SIZE, BY ANTIBACTERIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIODEFENSE MARKET SIZE, BY ANTITOXINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIODEFENSE MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIODEFENSE MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIODEFENSE MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIODEFENSE MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIODEFENSE MARKET SIZE, BY SELF AMPLIFYING MRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIODEFENSE MARKET SIZE, BY PROTEIN SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIODEFENSE MARKET SIZE, BY ADENOVIRUS BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIODEFENSE MARKET SIZE, BY POXVIRUS BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIODEFENSE MARKET SIZE, BY DETECTION & DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIODEFENSE MARKET SIZE, BY PREVENTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIODEFENSE MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIODEFENSE MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIODEFENSE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIODEFENSE MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIODEFENSE MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIODEFENSE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIODEFENSE MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIODEFENSE MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIODEFENSE MARKET SIZE, BY BACTERIAL AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIODEFENSE MARKET SIZE, BY TOXINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIODEFENSE MARKET SIZE, BY VIRAL AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS BIODEFENSE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES BIODEFENSE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 78. CANADA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 79. CANADA BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 80. CANADA BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 81. CANADA BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 82. CANADA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 83. CANADA BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 84. CANADA BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 85. CANADA BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 86. CANADA BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. CANADA BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. CANADA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. CANADA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 90. MEXICO BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 91. MEXICO BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 92. MEXICO BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 93. MEXICO BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 94. MEXICO BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 95. MEXICO BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 96. MEXICO BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 97. MEXICO BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 98. MEXICO BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. MEXICO BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. MEXICO BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. MEXICO BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 151. GERMANY BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 152. GERMANY BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 153. GERMANY BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 154. GERMANY BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 155. GERMANY BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 156. GERMANY BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 157. GERMANY BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 158. GERMANY BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 159. GERMANY BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 160. GERMANY BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. GERMANY BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. GERMANY BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 163. FRANCE BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 164. FRANCE BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 165. FRANCE BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 166. FRANCE BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 167. FRANCE BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 168. FRANCE BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 169. FRANCE BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 170. FRANCE BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 171. FRANCE BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. FRANCE BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. FRANCE BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. FRANCE BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 175. RUSSIA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 176. RUSSIA BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 177. RUSSIA BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 178. RUSSIA BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 179. RUSSIA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 181. RUSSIA BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 182. RUSSIA BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 183. RUSSIA BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 184. RUSSIA BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. RUSSIA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. RUSSIA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 187. ITALY BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 188. ITALY BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 189. ITALY BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 190. ITALY BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 191. ITALY BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 192. ITALY BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 193. ITALY BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 194. ITALY BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 195. ITALY BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 196. ITALY BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. ITALY BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. ITALY BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 199. SPAIN BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 200. SPAIN BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 201. SPAIN BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 202. SPAIN BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 203. SPAIN BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 204. SPAIN BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 205. SPAIN BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 206. SPAIN BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 207. SPAIN BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 208. SPAIN BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. SPAIN BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. SPAIN BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 224. SAUDI ARABIA BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 226. SAUDI ARABIA BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. SAUDI ARABIA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 247. DENMARK BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 248. DENMARK BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 249. DENMARK BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 250. DENMARK BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 251. DENMARK BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 252. DENMARK BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 253. DENMARK BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 254. DENMARK BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 255. DENMARK BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 256. DENMARK BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. DENMARK BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. DENMARK BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 268. NETHERLANDS BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. NETHERLANDS BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 270. NETHERLANDS BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 271. QATAR BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 272. QATAR BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 273. QATAR BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 274. QATAR BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 275. QATAR BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 276. QATAR BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 277. QATAR BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 278. QATAR BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 279. QATAR BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 280. QATAR BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. QATAR BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. QATAR BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 283. FINLAND BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 284. FINLAND BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 285. FINLAND BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 286. FINLAND BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 287. FINLAND BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 288. FINLAND BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 289. FINLAND BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 290. FINLAND BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 291. FINLAND BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 292. FINLAND BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 293. FINLAND BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. FINLAND BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 295. SWEDEN BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 296. SWEDEN BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 297. SWEDEN BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 298. SWEDEN BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 299. SWEDEN BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 300. SWEDEN BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 301. SWEDEN BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 302. SWEDEN BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 303. SWEDEN BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 304. SWEDEN BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 305. SWEDEN BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 306. SWEDEN BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 307. NIGERIA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 308. NIGERIA BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 309. NIGERIA BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 310. NIGERIA BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 311. NIGERIA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 312. NIGERIA BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 313. NIGERIA BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 314. NIGERIA BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 315. NIGERIA BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 316. NIGERIA BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 317. NIGERIA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 318. NIGERIA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 319. EGYPT BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 320. EGYPT BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 321. EGYPT BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 322. EGYPT BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 323. EGYPT BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 324. EGYPT BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 325. EGYPT BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 326. EGYPT BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 327. EGYPT BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 328. EGYPT BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 329. EGYPT BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 330. EGYPT BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 331. TURKEY BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 332. TURKEY BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 333. TURKEY BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 334. TURKEY BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 335. TURKEY BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 336. TURKEY BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 337. TURKEY BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 338. TURKEY BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 339. TURKEY BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 340. TURKEY BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 341. TURKEY BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 342. TURKEY BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 343. ISRAEL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 344. ISRAEL BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 345. ISRAEL BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 346. ISRAEL BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 347. ISRAEL BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 348. ISRAEL BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 349. ISRAEL BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 350. ISRAEL BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 351. ISRAEL BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 352. ISRAEL BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 353. ISRAEL BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 354. ISRAEL BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 355. NORWAY BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 356. NORWAY BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 357. NORWAY BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 358. NORWAY BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 359. NORWAY BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 360. NORWAY BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 361. NORWAY BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 362. NORWAY BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 363. NORWAY BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 364. NORWAY BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 365. NORWAY BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 366. NORWAY BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 367. POLAND BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 368. POLAND BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 369. POLAND BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 370. POLAND BIODEFENSE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 371. POLAND BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 372. POLAND BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 373. POLAND BIODEFENSE MARKET SIZE, BY MRNA VACCINES, 2018-2030 (USD MILLION)
TABLE 374. POLAND BIODEFENSE MARKET SIZE, BY VIRAL VECTOR VACCINES, 2018-2030 (USD MILLION)
TABLE 375. POL

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Biodefense market report include:
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Merck KGaA
  • Bio-Rad Laboratories, Inc.
  • PerkinElmer, Inc.
  • QIAGEN N.V.
  • bioMérieux SA
  • Agilent Technologies, Inc.
  • Bruker Corporation
  • Luminex Corporation

Table Information

Report AttributeDetails
No. of Pages186
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 22.71 Billion
Forecasted Market Value ( USD ) by 2030 $ 38.77 Billion
Compound Annual Growth Rate11.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Biodefense - Global Strategic Business Report - Product Image

Biodefense - Global Strategic Business Report

  • Report
  • 363 Pages
  • Global
From
Biodefense - A Global Market Overview - Product Image

Biodefense - A Global Market Overview

  • Report
  • 255 Pages
  • Global
From
Biodefense Market Report 2025 - Product Image

Biodefense Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Bio-Detection - Global Strategic Business Report - Product Image

Bio-Detection - Global Strategic Business Report

  • Report
  • 281 Pages
  • Global
From
Biological Safety Testing Services Market Size, Share & Trends Analysis Report by Services (Sterility Testing Services, Endotoxin Testing Services), Application, End-Use, and Region with Growth Forecasts, 2025-2030 - Product Image

Biological Safety Testing Services Market Size, Share & Trends Analysis Report by Services (Sterility Testing Services, Endotoxin Testing Services), Application, End-Use, and Region with Growth Forecasts, 2025-2030

  • Report
  • 150 Pages
  • Global
From

About the Biodefense Market

The Biodefense market is a sector of the biotechnology industry that focuses on the development of products and services to protect against biological threats. This includes the development of vaccines, diagnostics, and treatments for infectious diseases, as well as the development of countermeasures to protect against bioterrorism. Biodefense products are designed to protect against a wide range of biological agents, including bacteria, viruses, and toxins. The Biodefense market is driven by the need to protect against the increasing threat of biological agents, as well as the need to develop treatments for existing and emerging infectious diseases. Governments, healthcare organizations, and private companies are investing in the development of biodefense products and services. Some of the major companies in the Biodefense market include Emergent BioSolutions, GlaxoSmithKline, Johnson & Johnson, Merck, Novavax, Pfizer, and Sanofi. These companies are developing a range of products and services to protect against biological threats, including vaccines, diagnostics, and treatments. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.